Intrinsiqq
Calidi Biotherapeutics Inc. logo

Calidi Biotherapeutics Inc. Quality Score

CLDI

Compare
Quality19

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
90/100
11.9x

Under 20x, reasonable relative to earnings

Business Quality & Capital Allocation

Capital Structure
100/100
-$3M

Net cash position, no leverage concern

2022
$93892
$7.00M
TTM
$4.00M
$1.00M
CashDebt
Return on Capital
0/100
-253.2%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Calidi Biotherapeutics (CLDI) quality: score, margins and returns

Calidi Biotherapeutics (CLDI) scores 19/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 3 metrics each scored 0 to 100 and -253.2% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Calidi Biotherapeutics (CLDI) a high-quality business?+

Calidi Biotherapeutics scores 19 out of 100 on Intrinsiqq's quality score, a weighted blend of 3 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -253.2% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Calidi Biotherapeutics's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from CLDI's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Calidi Biotherapeutics scores well and where it falls behind.

What is Calidi Biotherapeutics's return on invested capital (ROIC)?+

Calidi Biotherapeutics earns about -253.2% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to CLDI's margins and growth on this scorecard to judge durability.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 11 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 13 Nov 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CLDI

CompareIntrinsic value
INMBInmune Bio Inc.
$0.83-7.49%10
BCDABioCardia, Inc.
$0.79+2.60%26
ENZNViskase Holdings, Inc.
$4.35-1.14%0
SNTISenti Biosciences Inc.
$2.79-2.82%0
ALLOAllogene Therapeutics Inc.
$0.63-6.31%10
EXOZExozymes Inc.
$2.91-14.05%10
AIMAIM ImmunoTech Inc.
$0.11-4.50%25
CADLCandel Therapeutics Inc.
$5.04-1.75%10

Spot a number that looks wrong? Check it in CLDI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing CLDI

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.